Literature DB >> 23879320

Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality.

A G Frostegård1, X Hua, J Su, J J Carrero, O Heimbürger, P Bárány, P Stenvinkel, J Frostegård.   

Abstract

The risk of premature death is high in haemodialysis (HD) patients. Antibodies against cardiolipin (anti-CL) are thrombogenic in diseases such as systemic lupus erythematosus (SLE). CL is easily oxidized (Ox) and plays a role in apoptosis. In this work we studied immunoglobulin (Ig)M anti-CL and anti-OxCL in HD-patients. We conducted an observational study with a prospective follow-up examining the relationship between anti-CL, anti-OxCL and mortality risk in a well-characterized cohort of 221 prevalent HD patients [56% men, median age 66 (interquartile range 51-74) years, vintage time 29 (15-58) months] with a mean follow-up period of 41 (20-48 months). According to the receiver operator characteristic (ROC) analysis, anti-OxCL [area under the curve (AUC) 0·62, P < 0·01], but not anti-CL (AUC 0·52, P = 0·2), is associated with mortality. In crude and adjusted Cox analysis, every log increase in anti-OxCL inversely predicted all-cause [adjusted hazard ratios (HR) 0·62 (0·43-0·89)] and CVD-related [adjusted HR 0·56 (0·32-0·98)] mortality. Patients with anti-OxCL levels below median also had increased all-cause and cardiovascular disease (CVD)-related mortality. Although anti-OxCL and anti-phosphorylcholine (PC) were related positively to each other (ρ = 0·57, P < 0·01), patients with one or two of these autoantibody levels below the median were associated with an incrementally increased death risk. Anti-OxCL were co-factor β2-GPI-independent; anti-CL from patients with anti-phospholipid antibody syndrome were β2-GPI-dependent, while sera from HD-patients less so. Sera from healthy donors was not β2-GPI-dependent. Anti-OxCL IgM is β2-glycoprotein 1 (GPI)-independent and a novel biomarker; low levels are associated with death among HD patients (and high levels with decreased risk). Combination with anti-PC increases this association. Putative therapeutic implications warrant further investigation.
© 2013 British Society for Immunology.

Entities:  

Keywords:  antibodies; atherosclerosis; cardiolipin; cardiovascular disease; haemodialysis; inflammation

Mesh:

Substances:

Year:  2013        PMID: 23879320      PMCID: PMC3826310          DOI: 10.1111/cei.12181

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Cardiolipin is a normal component of human plasma lipoproteins.

Authors:  H Deguchi; J A Fernandez; T M Hackeng; C L Banka; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 2.  Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes.

Authors:  Michael Schlame
Journal:  J Lipid Res       Date:  2007-12-12       Impact factor: 5.922

Review 3.  Lp-PLA2: a new kid on the block.

Authors:  Andrew Zalewski; Jeanenne J Nelson; Lisa Hegg; Colin Macphee
Journal:  Clin Chem       Date:  2006-07-27       Impact factor: 8.327

4.  Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men.

Authors:  Beatrice G Sjöberg; Jun Su; Ingrid Dahlbom; Hans Grönlund; Max Wikström; Bo Hedblad; Göran Berglund; Ulf de Faire; Johan Frostegård
Journal:  Atherosclerosis       Date:  2008-07-19       Impact factor: 5.162

5.  Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.

Authors:  J Frostegård; A K Ulfgren; P Nyberg; U Hedin; J Swedenborg; U Andersson; G K Hansson
Journal:  Atherosclerosis       Date:  1999-07       Impact factor: 5.162

6.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.

Authors:  P M Ridker; M J Stampfer; N Rifai
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

7.  Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors.

Authors:  Valerian E Kagan; Vladimir A Tyurin; Jianfei Jiang; Yulia Y Tyurina; Vladimir B Ritov; Andrew A Amoscato; Anatoly N Osipov; Natalia A Belikova; Alexandr A Kapralov; Vidisha Kini; Irina I Vlasova; Qing Zhao; Meimei Zou; Peter Di; Dimitry A Svistunenko; Igor V Kurnikov; Gregory G Borisenko
Journal:  Nat Chem Biol       Date:  2005-08-14       Impact factor: 15.040

Review 8.  C-reactive protein in end-stage renal disease: are there reasons to measure it?

Authors:  Peter Stenvinkel; Bengt Lindholm
Journal:  Blood Purif       Date:  2005       Impact factor: 2.614

Review 9.  Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?

Authors:  Peter Stenvinkel; Juan Jesús Carrero; Jonas Axelsson; Bengt Lindholm; Olof Heimbürger; Ziad Massy
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-09       Impact factor: 8.237

10.  Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite.

Authors:  Juan Jesús Carrero; Abdul Rashid Qureshi; Jonas Axelsson; Carla María Avesani; Mohammed E Suliman; Sawako Kato; Peter Bárány; Sunna Snaedal-Jonsdottir; Anders Alvestrand; Olof Heimbürger; Bengt Lindholm; Peter Stenvinkel
Journal:  Am J Clin Nutr       Date:  2007-03       Impact factor: 7.045

View more
  4 in total

Review 1.  The role of mitochondria in rheumatic diseases.

Authors:  Yann L C Becker; Bhargavi Duvvuri; Paul R Fortin; Christian Lood; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2022-09-29       Impact factor: 32.286

2.  Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development.

Authors:  Anna G Frostegård; Jun Su; Xiang Hua; Max Vikström; Ulf de Faire; Johan Frostegård
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

3.  Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes.

Authors:  Shailesh Kumar Samal; Abdul Rashid Qureshi; Mizanur Rahman; Peter Stenvinkel; Johan Frostegård
Journal:  J Clin Med       Date:  2020-03-11       Impact factor: 4.241

4.  Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality.

Authors:  S K Samal; A R Qureshi; M Rahman; P Stenvinkel; J Frostegård
Journal:  Clin Exp Immunol       Date:  2020-05-18       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.